Κυριακή 27 Ιουνίου 2021

New European Medicines Agency approval: Tucatinib in association with trastuzumab and capecitabine for the treatment of HER2-positive metastatic breast cancer previously treated

xlomafota13 shared this article with you from Inoreader

Bull Cancer. 2021 Jun 22:S0007-4551(21)00175-2. doi: 10.1016/j.bulcan.2021.04.004. Online ahead of print.

NO ABSTRACT

PMID:34172272 | DOI:10.1016/j.bulcan.2021.04.004

View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου